Bio-Path Holdings, Inc. (BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Peter Nielsen, President and Chief Executive Officer, will present a company overview at the Rodman & Renshaw Annual Global Investment Conference in New York City on Tuesday, September 11, 2012 at 11:15 a.m. Eastern Time.
A webcast of Mr. Nielsen’s remarks will be available live. You can access the webcast at the Company’s website:
BPTH presented at the annual BIO investor forum in San Francisco this morning. I found the presentation presented new information.
The fourth cohort is complete and we are awaiting results. There was no indication from the CEO that anything but success occurred.
Bio-path holdings has decided to extend their private financing efforts to January of 2013. They will now attempt to raise a total of $4 million versus the $2 million they previously were attempting to raise ending in October of 2012. The only reason given by the CEO was that response to the private placement enabled same.
The most exciting information was that M.D. Anderson Cancer Center is in discussions with Bio-path holdings to apply their technology for triple negative breast cancer treatment.
The CEO believes this company is at an inflection point as an investment. I hope he is right and the inflection point is from minus to plus.